A study of 614 fully vaccinated health workers in India found a “significant” drop in their Covid-fighting antibodies within four months of the first shot.
An outbreak of dengue fever is suspected of killing dozens of people in India’s northern state of Uttar Pradesh since the start of September, and authorities launched a campaign to destroy mosquito breeding grounds.
Bharat Biotech’s intranasal Covid-19 vaccine candidate is expected to enter the Phase II portion of a Phase II/III study within the next few weeks. BBV154 marks the second vaccine against the novel coronavirus developed by the India-based company.
Indian drug developer Hetero received emergency use approval from the country’s health authorities to make a generic version of Roche Holding AG’s Covid-19 drug.
India’s drug regulator granted emergency use approval for Zydus Cadila’s Covid-19 vaccine, the world’s first DNA shot against the coronavirus, in adults and children aged 12 years and older.
Bharat Biotech’s a two-dose, injectable Covid-19 vaccine Covaxin is authorized in India for ages 12 and up. The company is moving forward with a second vaccine against the novel coronavirus with a different mode of administration.
Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.
Novavax Inc. on Aug. 5 again delayed the company’s timeline for seeking U.S. authorization for its two-dose Covid-19 vaccine, but expects to become a major distributor to lower and middle-income countries this year.
The Delta variant of the coronavirus is the cause of more than 80 percent of new U.S. Covid-19 cases, but the authorized vaccines remain more than 90 percent effective in preventing hospitalizations and deaths, said top U.S. infectious disease expert Anthony Fauci during a U.S. Senate hearing on July 20.
Sanofi SA and GlaxoSmithKline Plc received an approval from Indian authorities for a late-stage clinical trial of their protein-based Covid-19 vaccine candidate, the drugmakers said on July 8.